Companies and Offerings in the Blockchain in Pharmaceutical Market
See what the full report offers before you invest; our sample is customized to your business.
Get it for free now
| Company | Description |
| Guardtime | This significantly offers ‘proof of truth’ to ensure that data has not been tampered with & that supply chain leaders can believe the respective information. |
| BurstIQ | Its offerings include enterprise-level blockchain & AI-powered data solutions primarily for the pharmaceutical & life sciences industries. |
| Oracle | This facilitates a complete set of blockchain, with an emphasis on protecting supply chains, ensuring drug authenticity, & controlling clinical trials. |
| Systech | Its offering combines traditional serialization & track-and-trace technology with sophisticated blockchain & AI capabilities. |
| PharmaLedger Association | This firm explored AstraLabel for electronic product information (ePI), AstraTrace for supply chain visibility, & decentralized clinical trial management |
| PharmaTrail AG | A company specializes in blockchain-enabled solutions for the pharmaceutical, biotech, & medtech sectors. |
| IBM | It emphasizes supply chain transparency, drug integrity, & regulatory compliance. |
| Blockchain Industry Group (BIG) | Through the alliances, this offers blockchain-based solutions for the pharmaceutical area based on supply chain integrity, transparency, & anti-counterfeiting via the MediLedger network. |
Market Forecast 2026-2035
The global blockchain in pharmaceutical market size was estimated at USD 1.14 billion in 2025 and is predicted to increase from USD 1.43 billion in 2026 to approximately USD 11.23 billion by 2035, expanding at a CAGR of 25.7% from 2026 to 2035.
The Pharma & Biopharma Manufacturers Segment Was Dominant in the Market in 2025
| Segment | Share 2025 (%) |
| Pharma & Biopharma Manufacturers | 46% |
| CMOs/CDMOs | 22% |
| Healthcare Providers & Health Systems | 14% |
| Supply Chain Intermediaries | 12% |
| Others | 6% |
Now it’s effortless to manage all your Pharmaceutical Market data in one powerful place - access the dashboard
Explanation
- Pharma & Biopharma Manufacturers account for 46% of the market, dominating due to their substantial demand for advanced solutions in drug production and biopharmaceutical manufacturing.
- CMOs/CDMOs represent 22% of the market and are the fastest growing segment, driven by increasing outsourcing of manufacturing and development services in the pharmaceutical industry.
- Healthcare Providers & Health Systems hold 14% of the market, supporting clinical care and health services but with a smaller share compared to manufacturers.
- Supply Chain Intermediaries account for 12% of the market, facilitating logistics and distribution, though their role is less dominant than the pharmaceutical manufacturers.
- Others make up 6% of the market, covering a variety of specialized end-users with a smaller share in the industry.
In 2025, the pharma & biopharma manufacturers segment registered dominance in the blockchain in pharmaceutical market by 46% in 2025. Dominance is led by the surging need to comply with strict regulations of the US Drug Supply Chain Security Act (DSCSA) and the EU Falsified Medicines Directive (FMD), rising demand to boost operational efficiency, lower spending, and adapt to advanced integrations. Mainly in tracking and tracing of drugs from raw materials to patients, blockchains bolster ensuring authenticity & preserving brand reputation.
Moreover, the CMOs/CDMOs segment is anticipated to expand at a rapid CAGR. Eventual developments are posing the wider adoption of Smart/Pharma 4.0 environments, where blockchain serves as a trust layer for automated, data-driven production for CMOs. Besides this, advanced technology is allowing for strategic alliances, which evolve into one-stop-shop circumstances for perfect data sharing around the comprehensive development-to commercialization chain.
What are the Key Developments in the Blockchain in Pharmaceutical Market?
- In January 2026, the Indian Pharmacopoeia Commission launched a novel QR code-based verification system to support consumers in checking the authenticity of drugs.
- In October 2025, Former ISRO scientist Abhishek Chakrala introduced PranaChain, a decentralized blockchain-powered healthcare platform to ensure secure, transparent, & consent-driven exchange of medical data.
- In September 2025, Hua Jian and Renhe rolled out the foremost global RWA platform for OTC drug transactions.
Keypoints
- Company Overview
- Locations Subsidiaries/Geographic reach
- Key Executives
- Company Financials
- Patents registered
- SWOT Analysis
- Applications Catered
- Strategic collaborations
- Recent Developments
- Competitive Benchmarking